AndroGel Off-Label Uses With Evidence Levels

How AndroGel Works: Mechanism of Action

Testosterone gel delivers bioidentical testosterone through the stratum corneum into the dermal microcirculation, producing steady-state serum concentrations within 24 to 72 hours of daily application. The drug bypasses first-pass hepatic metabolism, which distinguishes it from oral testosterone formulations that carry a higher risk of liver toxicity [1].

Once absorbed, testosterone binds the androgen receptor in target tissues (skeletal muscle, bone, brain, adipose, erythroid progenitor cells) and also undergoes conversion to dihydrotestosterone (DHT) via 5-alpha reductase and to estradiol via aromatase. These three molecules account for the breadth of testosterone's physiologic effects [2]. Steady-state pharmacokinetics matter clinically: the 2018 Endocrine Society guideline specifies that the goal of testosterone replacement is to "restore testosterone concentrations to the normal range for young men (450-600 ng/dL midpoint)" rather than to push levels supraphysiologic [2].

The gel formulation allows dose titration in small increments (typically 1.25 g steps for the 1.62% formulation), which makes it attractive for off-label applications in women or older men where lower, carefully controlled dosing is needed. Peak serum T levels occur approximately 2 to 8 hours after application and decline gradually, mimicking a blunted version of the natural diurnal testosterone rhythm [1].

Off-Label Use: Female Hypoactive Sexual Desire Disorder (HSDD)

Evidence Level: 1 (multiple RCTs and meta-analyses)

This is the best-studied off-label application of transdermal testosterone. A 2017 systematic review and meta-analysis of 36 RCTs (N=8,480 women) found that transdermal testosterone significantly increased the number of satisfying sexual episodes (mean difference +0.85/4 weeks, 95% CI 0.52-1.18) and sexual desire scores compared with placebo [3].

The 2019 Global Consensus Position Statement on Testosterone Therapy for Women, published in The Lancet Diabetes & Endocrinology and endorsed by multiple international societies, concluded that "there is good evidence for a treatment effect of testosterone on sexual function in postmenopausal women, with the strongest effect on desire" [4]. The same statement recommended transdermal formulations specifically, noting that oral testosterone preparations should not be used due to adverse lipid effects.

Doses used in female HSDD studies are roughly one-tenth of male replacement doses. A common protocol applies 5 mg of testosterone cream or approximately 0.5 mL of a 1% gel daily, targeting a serum total testosterone of 20 to 50 ng/dL. The Endocrine Society does not currently endorse testosterone therapy in women due to limited long-term safety data beyond 24 months [2], but clinicians routinely prescribe it, particularly when other interventions (flibanserin, bremelanotide) fail or produce intolerable side effects.

Monitoring for androgenic side effects (acne, hirsutism, voice deepening) is required at 3, 6, and 12 months. Discontinuation rates in RCTs for androgenic adverse events were low (typically <5%), but irreversible virilization is possible if dosing is not carefully controlled [4].

Off-Label Use: Sexual Function in Older Men Without Classic Hypogonadism

Evidence Level: 1 (RCT data from T-Trials)

The Testosterone Trials (TTrials) enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and symptoms consistent with low T, but who did not necessarily meet the strict diagnostic criteria for classical hypogonadism [5]. In the Sexual Function Trial, men randomized to testosterone gel (AndroGel 1%) for 12 months reported a statistically significant improvement in sexual desire (measured by the Derogatis Interview for Sexual Functioning) and erectile function compared with placebo.

The effect size was moderate. Sexual activity increased by a mean of 0.58 activities per day in the testosterone group vs. 0.15 in placebo (P<0.001) [5]. This benefit persisted across the 12-month treatment period but was not assessed after discontinuation. The Endocrine Society guideline acknowledges this evidence but notes that "testosterone treatment should not be offered to all older men with low testosterone concentrations" and should be reserved for those with "unequivocally low serum testosterone and clinically significant signs and symptoms" [2].

Off-Label Use: Age-Related Low Bone Mineral Density

Evidence Level: 1 (RCT data from T-Trials Bone Sub-Study)

The T-Trials Bone sub-study used quantitative computed tomography (QCT) rather than standard DXA, providing volumetric bone mineral density (vBMD) measurements that better capture cortical and trabecular compartments separately [6]. After 12 months of testosterone gel, lumbar spine trabecular vBMD increased by 7.5% vs. placebo, and estimated bone strength (by finite element analysis) increased by 10.8% at the spine.

Hip vBMD showed smaller but significant gains. These results established that testosterone has direct skeletal effects in older men with low T levels, independent of its conversion to estradiol. The 2020 Endocrine Society Scientific Statement noted that "testosterone therapy increased volumetric bone mineral density and estimated bone strength" in the TTrials, but fracture reduction has not been demonstrated in any testosterone trial to date [6].

This gap matters. Without fracture endpoint data, off-label prescribing of testosterone gel for osteoporosis prevention remains a secondary strategy behind bisphosphonates, denosumab, and other agents with proven anti-fracture efficacy. Clinicians may reasonably add testosterone gel in men who have both symptomatic hypogonadism and low bone density, treating two conditions simultaneously.

Off-Label Use: Unexplained Anemia in Older Men

Evidence Level: 1 (RCT data from T-Trials Anemia Sub-Study)

Unexplained anemia affects 16% to 20% of men over age 65. The T-Trials Anemia sub-study found that testosterone gel corrected anemia (hemoglobin rising to above 12.7 g/dL) in 54% of men with unexplained anemia vs. 15% with placebo (P<0.001) [7]. Among men with anemia of known cause, the correction rate was 52% vs. 19%.

These results led Roy et al. to write in JAMA Internal Medicine that "testosterone treatment significantly increased hemoglobin levels in older men with unexplained anemia" [7]. The hematologic response was clinically meaningful, with mean hemoglobin increases of 1.0 g/dL. Erythrocytosis (hematocrit above 54%) occurred in approximately 4% of testosterone-treated men, requiring dose reduction or temporary discontinuation.

This is one of the more compelling off-label applications because existing treatments for unexplained anemia in older men are limited. Erythropoiesis-stimulating agents carry their own cardiovascular risks. Testosterone gel offers a once-daily topical alternative with a defined monitoring protocol (hematocrit checks at 3, 6, and 12 months).

Off-Label Use: Depressive Symptoms in Hypogonadal Men

Evidence Level: 2 (RCT with positive signal but mixed replication)

The T-Trials Vitality sub-study assessed mood using the Patient Health Questionnaire-9 (PHQ-9) and found a modest but statistically significant improvement in the testosterone group compared with placebo at 12 months [5]. Earlier, smaller RCTs had suggested antidepressant effects, particularly in men with both low testosterone and mild-to-moderate depression who had not responded fully to SSRIs.

A 2019 meta-analysis of 27 RCTs (N=1,890) in JAMA Psychiatry found that testosterone treatment was associated with reduced depressive symptoms (effect size g=0.21, 95% CI 0.10-0.32), with stronger effects in studies that achieved physiologic testosterone levels and in men receiving higher doses [8]. The effect was roughly half that of standard antidepressant therapy.

The evidence does not support testosterone as monotherapy for major depressive disorder. Its role is more nuanced: as augmentation therapy in hypogonadal men with incomplete SSRI response, or for depressive symptoms in the context of testosterone replacement for a primary indication. The Endocrine Society guideline does not list depression as a standalone indication for testosterone therapy [2].

Off-Label Use: Sarcopenia and Lean Mass Preservation

Evidence Level: 2 (RCTs showing body composition changes without functional endpoint confirmation)

Multiple RCTs confirm that testosterone gel increases lean body mass and decreases fat mass. The T-Trials Physical Function sub-study showed that testosterone-treated men walked significantly farther on the 6-minute walk test (improvement of 14.3 meters vs. 4.0 meters with placebo), though this difference was not statistically significant for the secondary endpoint of stair-climbing power [5].

A larger body of evidence comes from studies in younger hypogonadal men. The 2018 Endocrine Society guideline acknowledges that "testosterone therapy increases lean mass and decreases fat mass" but states that "the long-term clinical benefits of changes in body composition have not been established" [2]. The disconnect between body composition improvement and functional outcomes (falls prevention, disability reduction, survival) is the primary reason this use remains off-label with moderate rather than strong evidence.

For clinicians considering testosterone gel in older men with sarcopenia, the practical approach is to combine it with resistance exercise, which has additive effects on lean mass. Testosterone alone without exercise produces smaller and potentially less clinically meaningful gains in physical performance [9].

Off-Label Use: Cognitive Function in Older Men

Evidence Level: 3 (RCT data negative for primary outcome)

The T-Trials Cognitive Function sub-study randomized men to testosterone gel vs. placebo and assessed memory, executive function, and spatial ability at 12 months. The primary outcome (delayed paragraph recall from the Wechsler Memory Scale) showed no significant difference between groups [10]. Some secondary measures of spatial ability improved, but the overall cognitive profile did not change meaningfully.

This null result is important. Observational studies and small, uncontrolled trials had suggested that testosterone might protect against cognitive decline or even reduce Alzheimer's risk. The TTrials cognitive data, while limited to 12 months, did not support this hypothesis. Resnick et al. concluded in JAMA that "among older men with low testosterone and age-associated memory impairment, testosterone treatment for 1 year did not improve memory or other cognitive functions" [10].

Prescribing testosterone gel for cognitive preservation is not supported by current evidence. Clinicians should counsel patients that while testosterone replacement for a primary indication will not worsen cognition, it also should not be expected to serve as a neuroprotective agent.

Off-Label Use: HIV-Associated Wasting and Muscle Loss

Evidence Level: 2 (older RCTs with consistent direction)

Before effective antiretroviral therapy, HIV-associated wasting was a common indication for testosterone supplementation. Bhasin et al. demonstrated in a 2000 RCT that testosterone (via injection, though gel formulations have since been used) combined with resistance exercise increased lean body mass by 3.2 kg over 16 weeks in HIV-positive men with weight loss, compared with 0.6 kg in the placebo-plus-exercise group [11].

Current relevance is narrower. With modern ART, severe wasting is less common, but HIV-positive men still experience hypogonadism at higher rates than the general population (estimated 25% to 40% depending on disease stage and ART regimen). Testosterone gel is used in this population both for symptomatic hypogonadism and for the anabolic benefit on lean mass. The HIV Medicine Association guidelines acknowledge testosterone replacement as appropriate when hypogonadism is confirmed biochemically.

Cardiovascular Safety Across Off-Label Applications

Any discussion of off-label testosterone prescribing must address cardiovascular risk. The TRAVERSE trial (N=5,246), published in 2023, was a placebo-controlled, event-driven cardiovascular safety trial in men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease [12]. At a median follow-up of 33 months, the incidence of major adverse cardiovascular events (MACE) was 7.0% in the testosterone group vs. 7.3% in placebo (hazard ratio 0.96, 95% CI 0.78-1.17).

This result was reassuring. It did not demonstrate cardiovascular benefit, but it excluded the excess risk that older observational studies had suggested. The FDA's 2015 label update requiring a cardiovascular warning on all testosterone products predated TRAVERSE; whether the label will be revised in light of these data remains to be seen [12].

For off-label prescribing specifically, the TRAVERSE data provides some reassurance that short-to-medium-term testosterone gel use in men with cardiovascular risk factors does not produce excess MACE. Clinicians should still monitor hematocrit (erythrocytosis raises thrombotic risk) and blood pressure at regular intervals.

Evidence-Level Summary

| Off-Label Use | Evidence Level | Key Study | Direction | |---|---|---|---| | Female HSDD | Level 1 | Achilli et al. meta-analysis (N=8,480) | Positive | | Sexual function, older men | Level 1 | T-Trials (N=790) | Positive | | Bone mineral density | Level 1 | T-Trials Bone Sub-Study | Positive (no fracture data) | | Unexplained anemia | Level 1 | T-Trials Anemia Sub-Study | Positive | | Depressive symptoms | Level 2 | Meta-analysis of 27 RCTs (N=1,890) | Modest positive | | Sarcopenia / lean mass | Level 2 | Multiple RCTs | Positive for composition, uncertain for function | | HIV-associated wasting | Level 2 | Bhasin et al. 2000 | Positive | | Cognitive function | Level 3 | T-Trials Cognitive Sub-Study | Null |

Monitoring Protocol for Off-Label Testosterone Gel Use

Regardless of the indication, off-label testosterone gel use requires the same monitoring schedule recommended by the 2018 Endocrine Society guideline [2]. Check serum testosterone at 2 to 4 weeks after initiation (trough level, drawn 2 to 8 hours post-application for gel formulations). Measure hematocrit at baseline, 3 months, 6 months, and 12 months. If hematocrit exceeds 54%, reduce the dose or suspend therapy until it falls below 50%.

PSA should be measured at baseline and at 3 to 6 months. A confirmed increase of more than 1.4 ng/mL within 12 months warrants urology referral. Lipid panel and hepatic function tests are recommended at baseline and annually. In women receiving off-label testosterone for HSDD, total testosterone should be checked at 3 to 6 weeks and maintained below 50 ng/dL to minimize virilization risk [4].